Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Emmeline N. Taylor, Christine Timko, Ingrid A. Binswanger, Alex H. S. Harris, Matthew Stimmel, David Smelson & Andrea K. Finlay. (2022) A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration. Substance Abuse 43:1, pages 556-563.
Read now
Read now
Rachel P. Winograd, Jeremiah Weinstock, Aaron Ruiz, Bridget Coffey, Katherine Brown, Rithvik Kondai, Elizabeth Connors & Christine Smith. (2022) Addressing stimulant use disorder through state opioid response grants from the substance abuse and mental health services administration: Missouri’s initial approach. The American Journal of Drug and Alcohol Abuse 48:6, pages 644-650.
Read now
Read now
Virgil Lee Gregory$suffix/text()$suffix/text() & Rebecca J. Bartlett Ellis. (2020) Cognitive-behavioral therapy and buprenorphine for opioid use disorder: A systematic review and meta-analysis of randomized controlled trials. The American Journal of Drug and Alcohol Abuse 46:5, pages 520-530.
Read now
Read now
Maria Stevens, Erin Hubbard & Heather Leutwyler. (2020) Tools You'll Have for the Rest of Your Life: A Qualitative Evaluation of a Fitness and Vocational Training Program for Substance Use Recovery. Substance Use & Misuse 55:4, pages 628-635.
Read now
Read now
Ali Jalali. Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0.
Read now
Read now
Articles from other publishers (33)
Omeid Heidari, Abigail Winiker, Derek T. DangerfieldIIII, Jennifer Wenzel, Tamar Rodney, Shruti Mehta & Becky Genberg. (2023) Understanding healthcare engagement for people who inject drugs. Research in Nursing & Health 47:2, pages 242-250.
Crossref
Crossref
Bronwyn S. Bedrick, Caroline Cary, Carly O'Donnell, Christine Marx, Hayley Friedman, Ebony B. Carter, Nandini Raghuraman, Molly J. Stout, Benson S. Ku, Kevin Y Xu & Jeannie C. Kelly. (2024) County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit (“secret shopper”) study in Missouri. Drug and Alcohol Dependence Reports 10, pages 100218.
Crossref
Crossref
Lindsey M. Filiatreau, Hannah S. Szlyk, Erin Kasson, Megan F. Dickson, Devin Banks, Rachel Winograd, Phillip Marotta & Patricia Cavazos-Rehg. (2024) Attitudes and Subjective Norms Regarding Medication for Opioid Use Disorder Among Individuals in Treatment for Opioid Use Disorder in the Greater St. Louis Area. Journal of Drug Issues.
Crossref
Crossref
Rachel P. Winograd, Bridget Coffey, Melissa Nance & Ryan Carpenter. (2023) The association of medical providers’ attitudes about naloxone and treating people with opioid use disorder and their self-reported low-barrier treatment practices. Addictive Behaviors Reports 18, pages 100514.
Crossref
Crossref
Erin J. Stringfellow, Tse Yang Lim, Huiru Dong, Ziyuan Zhang & Mohammad S. Jalali. (2023) The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine‐waivered providers in the United States. Addiction 118:11, pages 2215-2219.
Crossref
Crossref
Jennifer Miles, Peter Treitler, Richard Hermida, Amesika N. Nyaku, Kosali Simon, Sumedha Gupta, Stephen Crystal & Hillary Samples. (2023) Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. Drug and Alcohol Dependence 252, pages 110963.
Crossref
Crossref
Joseph Tay Wee Teck, Rosalind Gittins, Giedre Zlatkute, Alberto Oteo Pérez, Susanna Galea-Singer & Alexander Baldacchino. (2023) Developing a Theoretically Informed Implementation Model for Telemedicine-Delivered Medication for Opioid Use Disorder: Qualitative Study With Key Informants. JMIR Mental Health 10, pages e47186.
Crossref
Crossref
Rachel Winograd, Zach Budesa, Devin Banks, Ryan Carpenter, Claire A. Wood, Alex Duello, Paul Thater & Christine Smith. (2023) Outcomes of State Targeted/Opioid Response Grants and the Medication First Approach: Evidence of Racial Inequities in Improved Treatment Access and Retention. Substance Abuse 44:3, pages 184-195.
Crossref
Crossref
Erin J. Stringfellow, Tse Yang Lim, Catherine DiGennaro, Ziyuan Zhang, Pritika Paramasivam, Benjamin Bearnot, Keith Humphreys & Mohammad S. Jalali. (2023) Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis. Journal of Addiction Medicine 17:4, pages 439-446.
Crossref
Crossref
Kimberly L. Sue, Marek Chawarski, Leslie Curry, Ryan McNeil, Edouard CoupetJrJr, Robert P. Schwartz, Christine Wilder, Judith I. Tsui, Kathryn F. Hawk, Gail D’Onofrio, Patrick G. O’Connor, David A. Fiellin & E. Jennifer Edelman. (2023) Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs. JAMA Network Open 6:5, pages e2312718.
Crossref
Crossref
Honora Englander, Jessica Gregg & Ximena A. Levander. (2022) Envisioning Minimally Disruptive Opioid Use Disorder Care. Journal of General Internal Medicine 38:3, pages 799-803.
Crossref
Crossref
Jason M. Glanz, Ingrid A. Binswanger, Christina L. Clarke, Anh P. Nguyen, Morgan A. Ford, G. Thomas Ray, Stanley Xu, Rulin C. Hechter, Bobbi Jo H. Yarborough, Douglas W. Roblin, Brian Ahmedani, Joseph A. Boscarino, Susan E. Andrade, Carmen L. Rosa & Cynthia I. Campbell. (2022) The association between buprenorphine treatment duration and mortality: a multi‐site cohort study of people who discontinued treatment. Addiction 118:1, pages 97-107.
Crossref
Crossref
Caleb J. Banta-Green, Mandy D. Owens, Jason R. Williams, Jeanne M. Sears, Anthony S. Floyd, Wendy Williams-Gilbert & Susan Kingston. (2022) The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State. Addiction Science & Clinical Practice 17:1.
Crossref
Crossref
Erin F. Madden, Kristin K. Barker, Joshua Guerra, Corey Villanueva & Sandra H. Sulzer. (2022) Variation in intervention stigma among medications for opioid use disorder. SSM - Qualitative Research in Health 2, pages 100161.
Crossref
Crossref
Thomas J. Stopka, Rebecca E. Rottapel, Warren J. Ferguson, Ekaterina Pivovarova, Lizbeth Del Toro-Mejias, Peter D. Friedmann & Elizabeth A. Evans. (2022) Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. International Journal of Drug Policy 110, pages 103803.
Crossref
Crossref
Kathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, Martina Pavlicova, Jacquie King, Marc Fishman, Matisyahu Shulman, Aimee Campbell, Miranda Greiner, Jennifer Scodes, Sarah Meyers-Ohki, Patricia Novo, Edward Nunes & John Rotrosen. (2022) Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder. Drug and Alcohol Dependence Reports 5, pages 100100.
Crossref
Crossref
Åsa Kneck, Anna Klarare, Elisabet Mattsson & Martin Salzmann‐Erikson. (2022) Reflections on health among women in homelessness: A qualitative study. Journal of Psychiatric and Mental Health Nursing 29:5, pages 709-720.
Crossref
Crossref
Christine A. Fournier Bell, Mary K. McCurry, Mirinda B. Tyo & Jennifer Viveiros. (2022) Examination of Factors Affecting Therapeutic Attitude and Empowerment of Perianesthesia Nurses Who Care for Patients With Opioid Use Disorder. Journal of PeriAnesthesia Nursing 37:5, pages 669-677.
Crossref
Crossref
Madison Baumgart-McFarland, Elizabeth Chiarello & Tayla Slay. (2022) Reluctant Saviors: Professional ambivalence, cultural imaginaries, and deservingness construction in naloxone provision. Social Science & Medicine 309, pages 115230.
Crossref
Crossref
Ned J. Presnall, Giulia Croce Butler & Richard A. Grucza. (2022) Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study. Journal of Substance Abuse Treatment 139, pages 108788.
Crossref
Crossref
Claire A. Wood, Alex Duello, Jennifer Miles, Brenna Lohmann, Tatiana Gochez-Kerr, Kori Richardson, Rosie Anderson-Harper & Rachel P. Winograd. (2022) Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. Journal of Substance Abuse Treatment 138, pages 108747.
Crossref
Crossref
Emily Ledingham, Rachel Sayko Adams, Dennis Heaphy, Alex Duarte & Sharon Reif. (2022) Perspectives of adults with disabilities and opioid misuse: Qualitative findings illuminating experiences with stigma and substance use treatment. Disability and Health Journal 15:2, pages 101292.
Crossref
Crossref
Carolyn A. Chan, Bethany Canver, Ryan McNeil & Kimberly L. Sue. (2022) Harm Reduction in Health Care Settings. Medical Clinics of North America 106:1, pages 201-217.
Crossref
Crossref
Hannah Snyder, Mariah M. Kalmin, Aimee Moulin, Arianna Campbell, David Goodman-Meza, Howard Padwa, Serena Clayton, Melissa Speener, Steve Shoptaw & Andrew A. Herring. (2021) Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program. Annals of Emergency Medicine 78:6, pages 759-772.
Crossref
Crossref
Elizabeth Chiarello. (2021) Pharmacists should treat patients who have opioid use disorders, not police them. Journal of the American Pharmacists Association 61:6, pages e14-e19.
Crossref
Crossref
Jesse L. Yedinak, Yu Li, Maxwell S. Krieger, Katharine Howe, Colleen Daley Ndoye, Hyunjoon Lee, Anna M. Civitarese, Theodore Marak, Elana Nelson, Elizabeth A. Samuels, Philip A. Chan, Thomas Bertrand & Brandon D.L. Marshall. (2021) Machine learning takes a village: Assessing neighbourhood-level vulnerability for an overdose and infectious disease outbreak. International Journal of Drug Policy 96, pages 103395.
Crossref
Crossref
Kathryn Hawk, Lauretta E. Grau, David A. Fiellin, Marek Chawarski, Patrick G. O’Connor, Nikolas Cirillo, Chris Breen & Gail D’Onofrio. (2021) A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs. Academic Emergency Medicine 28:5, pages 542-552.
Crossref
Crossref
Eric C. Strain. (2021) Meaning and purpose in the context of opioid overdose deaths. Drug and Alcohol Dependence 219, pages 108528.
Crossref
Crossref
Benjamin R Brady, Rachel Gildersleeve, Bryna D Koch, Doug E Campos-Outcalt & Daniel J Derksen. (2021) Federally Qualified Health Centers Can Expand Rural Access to Buprenorphine for Opioid Use Disorder in Arizona. Health Services Insights 14, pages 117863292110375.
Crossref
Crossref
Darius A. Rastegar. 2021. Treating Opioid Use Disorder in General Medical Settings. Treating Opioid Use Disorder in General Medical Settings
1
7
.
Kelsey C. Priest, Dennis McCarty & Travis I. Lovejoy. (2020) Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration. Journal of General Internal Medicine 35:S3, pages 886-890.
Crossref
Crossref
Andrea K. Finlay, Erica Morse, Matthew Stimmel, Emmeline Taylor, Christine Timko, Alex H. S. Harris, David Smelson, Mengfei Yu, Jessica Blue-Howells & Ingrid A. Binswanger. (2020) Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study. Journal of General Internal Medicine 35:9, pages 2529-2536.
Crossref
Crossref
Rachel P. Winograd, Claire A. Wood, Erin J. Stringfellow, Ned Presnall, Alex Duello, Phil Horn & Tim Rudder. (2020) Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. Journal of Substance Abuse Treatment 108, pages 55-64.
Crossref
Crossref